We are OVID

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.

Developing BoldMedicine to Transform the Lives of People with Rare Neurological Disorders

ovid

What’s in a name?

Ovid Therapeutics is named for the Roman poet, Publius Ovidius Naso, known for his epic work, Metamorphoses or Books of Transformations.

Here at Ovid, each “Ovidian,” is a catalyst for transformation and change, contributing to a diverse environment that enhances our knowledge and growth. It is the diversity of our people and beliefs that drives our community and fuels our approach to both science and business.

“In the make-up of human beings,
intelligence counts for more than our hands,
and that is our true strength.”

– Ovid, Metamorphoses

Leadership

Jeremy M. Levin, D.Phil, MB BChir, has served as our chief executive officer since March 2015 and as chairman of our board of directors since April 2014. Prior to joining us, Dr. Levin served as president and chief executive officer, of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company, from May 2012 to October 2013. Dr. Levin joined Teva in February 2012. From September 2007 to December 2012, Dr. Levin held several roles at Bristol-Myers Squibb Company, a publicly held pharmaceutical company, finally serving as the senior vice president of strategy, alliances and transactions. Dr. Levin also served as a member of the executive committee at Bristol-Myers Squibb Company. Prior to that, Dr. Levin served as global head of strategic alliances at Novartis Institutes for Biomedical Research, Inc., a division of Novartis AG, from 2002 to 2007. Previously, he served on the board of directors of various public and private biopharmaceutical companies, including as chairman and chief executive officer of Cadus Pharmaceuticals Corporation, a drug development company. Dr. Levin currently serves on the board of directors of BioCon Ltd., a publicly held biopharmaceutical company, Lundbeck (OMX: LUN), and ZappRx, Inc., an e-health company. Dr. Levin is also a serving member on the board of the Biotechnology Innovation Organization. He has also served as a practicing physician at university hospitals in England, South Africa and Switzerland. Dr. Levin earned his B.A. in zoology, M.A. in cell biology and Ph.D. in chromatin structure, all from University of Oxford, and his MB and BChir from the University of Cambridge.

Matthew During, M.D., D.Sc., is our founder and was appointed as our chief scientific officer in March 2015 and has served as our president and a member of our board of directors since April 2014. From April 2014 to March 2015, he served as our chief executive officer. Prior to founding our company, Dr. During founded NightstaRx Limited, a pharmaceutical company, in October 2013 and served as a consultant until November 2015. From February 2014 to December 2014, Dr. During served as a senior manager at Bridgewater Associates. Prior to that, he founded Neurologix, Inc., a pharmaceutical company, in October 1999 and served as a member of its scientific advisory board until March 2012. Dr. During also co-founded Merlin Pharmaceuticals (P) Limited, a pharmaceutical company, in February 1993 and served a member of its scientific advisory board until December 1994. Dr. During previously served on the faculty of Yale University as Professor of Neurosurgery from 1989 to 2000, as a Professor at Cornell University until 2006 and Ohio State University from 2006 to December 2014, where he currently serves as an adjunct professor. Since 2011, he has also served as a visiting professor of translational neuroscience at the University of Oxford. Dr. During earned his B.S., M.D. and D.Sc. from the University of Auckland. He also completed fellowships at Massachusetts Institute of Technology and Harvard Medical School.

Yaron Werber, M.D., MBA, has served as the chief business officer since July 2016, as chief financial officer since June 2015, as secretary from July 2015 until September 2017, and as treasurer since April 2017. Prior to joining Ovid, Dr. Werber worked at Citigroup Global Markets Inc. from March 2004 to June 2015, where he most recently served as a managing director, and the head of U.S. healthcare and biotech equity research teams. Previously, Dr. Werber was a senior biotech analyst and vice president at SG Cowen Securities Corporation. He began his career in academic research and was director of business development at NotifyMD, Inc., an e-health company. Dr. Werber earned his B.S. in Biology from Tufts University and a combined M.D./MBA degree from Tufts University School of Medicine.

Amit Rakhit, M.D., MBA, has served as our chief medical and portfolio management officer since March 2016. Prior to joining us, Dr. Rakhit served as senior vice president, Worldwide Medical at Biogen Inc., a publicly held biotechnology company, from March 2014 to March 2016 and as vice president, program leadership & management from June 2011 to February 2014. Prior to that, he worked at Bristol-Myers Squibb Company from August 2001 to June 2011, where he most recently served as vice president, intercontinental medical. Dr. Rakhit earned his B.A. in molecular biology from the University of California, Berkeley, his M.D. from Tufts University School of Medicine, his M.S. from Vanderbilt University School of Medicine and dual MBAs from the London Business School and Columbia University. Dr. Rakhit completed his fellowship in pediatric cardiology at Harvard Medical School.

Ana Ward joined Ovid Therapeutics as Senior Vice President & General Counsel in September of 2017. Ana previously served as General Counsel, Executive Vice President Patient Access & Corporate Development, and Board Secretary of Rosetta Genomics, Ltd., overseeing public company reporting and executing licensing and partnership activities. Prior to Rosetta Genomics, Ana held a series of leadership roles within the Ambion family of companies, including Ambion, Inc. (acquired by Applied Biosystems), Asuragen, Inc. (a spin-off of Ambion, Inc.) and Mirna Therapeutics, Inc. (a spin-off of Asuragen, Inc.), where she was responsible for managing a diverse portfolio of legal matters such as intellectual property claims, compliance, trademark clearance, and strategic business interactions. Ana holds a bachelor of arts in French, a master of science in molecular biology and a masters of business administration, all from the University of Texas, Austin, and a juris doctorate from the University of Texas Law School. Ana also holds a master of science in bioscience regulatory affairs from Johns Hopkins University.

Dirk Haasner, Ph.D., M.P.M, is currently our senior vice president, global regulatory affairs and manufacturing. Dr. Haasner previously served as our vice president, global regulatory affairs from December 2015 to March 2016. Prior to joining us, Dr. Haasner was vice president regulatory and medical affairs, and vice president regulatory strategy and policy at Lundbeck USA, Inc., a H. Lundbeck A/S subsidiary, from February 2002 to November 2015, with responsibility for all FDA interactions on several marketed orphan drugs and all Lundbeck development compounds. From 1994 to 2002, Dr. Haasner was employed at F. Hoffmann-La Roche AG, a publicly held healthcare company, where he held positions of increasing responsibility in global product development and global strategic marketing before being appointed global life-cycle leader. Dr. Haasner co-founded the biotech start-up 4-Antibody AG that was acquired in 2014 by Agenus Inc., a publicly held biotechnology company. Dr. Haasner obtained a M.Sc. in molecular biology at the University of Basel, Switzerland, a Ph.D. in cell biology and immunology at the Basel Institute for Immunology, and holds a postgraduate degree in pharmaceutical medicine from the EUCOR Universities Basel, Strasbourg and Freiburg.

Suzanne Wakamoto has been a manager for 30 years and a human resources leader for over 20. Her diverse background includes start-up, global, multi-site and non-profit organizations. She has been fortunate to work and consult in an eclectic array of industries: arts education, biotechnology, construction, entertainment, manufacturing, retail and software. Since 2008, she served as an independent HR consultant where she partnered with clients to develop more cohesive and compliant HR practices that aligned with their corporate culture and business needs. Some of her former corporate positions include: heading HR for the internationally acclaimed Blue Man Group and director of HR & administration for Cadus Pharmaceutical Corporation. Suzanne sits on the board of directors of NYC SHRM, the New York City chapter of the Society of Human Resources Management and is a founder and current chair of HR-PRO, NYC SHRM’s award winning pro-bono outreach program. She holds a Bachelor’s degree in world arts and culture from UCLA. Ultimately, Suzanne is a person who believes excellence and fun are not mutually exclusive, but rather the partnership that makes us successful every day.

Timothy Daly has served as our vice president, finance and corporate controller since September 2015. Prior to joining us, Mr. Daly was vice president of finance and corporate controller at Advanced Health Media LLC from August 2013 to September 2015, a global provider of technology to healthcare professionals. From December 2011 to August 2013, Mr. Daly served as vice president, controller and chief accounting officer at Enzon Pharmaceuticals, Inc., a publicly held pharmaceuticals company. Prior to that, from 1999 to 2011, he served in various operation finance roles during his 12-year tenure at ImClone Systems Incorporated, a wholly owned subsidiary of Eli Lilly and Company, and most recently as director of finance. Mr. Daly earned his B.S. in accounting from Rider University.

Michael Ciraolo, J.D., Ph.D., is vice president, chief intellectual property counsel at Ovid Therapeutics. He is an intellectual property attorney with significant experience leading and implementing effective IP strategies in the areas of pharmaceuticals and biotechnology.

Prior to joining Ovid, Michael spent nine years at Forest Laboratories creating value through global patent prosecution for pharmaceutical products in all phases of development. He has conducted hundreds of due diligence evaluations related to M&A and in-licensing opportunities and has provided strategic advice related to the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act. Previously, Michael was an associate at Arent Fox PLLC and Baker Botts LLP in New York City. Michael received his B.S. in chemistry from SUNY at Brockport, his Ph.D. in chemistry from Stony Brook University and attended St. John’s University School of Law for his J.D.

Claude Nicaise, M.D., is head, strategic orphan regulatory affairs at Ovid Therapeutics.  He is a respected executive with over 20 years of significant product development experience, particularly in orphan diseases.

Prior to joining Ovid, Claude was an executive vice president of clinical development and regulatory affairs at Formula Pharmaceuticals, Inc. Before that, he was senior vice president, strategic product development and global regulatory affairs at Alexion Pharmaceuticals, where he managed all regulatory activities and co-managed development programs with the head of R&D and designed, interpreted and filed all programs supporting development in rare diseases. Prior to joining Alexion, Claude served in various positions of increasing responsibility at Bristol-Myers Squibb for 24 years. Claude holds an M.D. from the Université libre de Bruxelles in Belgium.

Claude is the author of more than 60 research articles published in peer-reviewed journals and is a member of several professional medical associations, including the American Society of Clinical Oncology; the European Society for Medical Oncology; the American Society for Microbiology; and the American Society of Hematology.

Board of Directors

Jeremy M. Levin, D.Phil, MB BChir, has served as our chief executive officer since March 2015 and as chairman of our board of directors since April 2014. Prior to joining us, Dr. Levin served as president and chief executive officer, of Teva Pharmaceutical Industries Ltd., a publicly held pharmaceutical company, from May 2012 to October 2013. Dr. Levin joined Teva in February 2012. From September 2007 to December 2012, Dr. Levin held several roles at Bristol-Myers Squibb Company, a publicly held pharmaceutical company, finally serving as the senior vice president of strategy, alliances and transactions. Dr. Levin also served as a member of the executive committee at Bristol-Myers Squibb Company. Prior to that, Dr. Levin served as global head of strategic alliances at Novartis Institutes for Biomedical Research, Inc., a division of Novartis AG, from 2002 to 2007. Previously, he served on the board of directors of various public and private biopharmaceutical companies, including as chairman and chief executive officer of Cadus Pharmaceuticals Corporation, a drug development company. Dr. Levin currently serves on the board of directors of BioCon Ltd., a publicly held biopharmaceutical company, Lundbeck (OMX: LUN), and ZappRx, Inc., an e-health company. Dr. Levin is also a serving member on the board of the Biotechnology Innovation Organization. He has also served as a practicing physician at university hospitals in England, South Africa and Switzerland. Dr. Levin earned his B.A. in zoology, M.A. in cell biology and Ph.D. in chromatin structure, all from University of Oxford, and his MB and BChir from the University of Cambridge.

Karen Bernstein, Ph.D. has served as a member of our board of directors since September 2015. Prior to joining us, Dr. Bernstein co-founded BioCentury Inc., or BioCentury, a provider of clinical, regulatory and finance news for the biotechnology and pharmaceutical industries, where she served as editor-in-chief from its inception in August 1992 to August 2015. From September 2015 to October 2016, she also served on the board of directors of Vitae Pharmaceuticals, Inc., which was acquired by Allergan Holdco US, Inc. Dr. Bernstein continues to serve as chairman of the board of directors of BioCentury. Dr. Bernstein earned her B.A. in politics and history from Brandeis University and her Ph.D. in political science from Stanford University.

Barbara Duncan, MBA, has served as a member of our board of directors since June 2017. She previously served as the chief financial officer and treasurer at Intercept Pharmaceuticals, Inc.  Prior to Intercept, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., including chief financial officer and ultimately serving as chief executive officer prior to DOV’s sale to Euthymics Bioscience, Inc. in 2010. Ms. Duncan has also held roles in the corporate finance groups at SBC Warburg Dillon Read, Inc. and Lehman Brothers Inc. She currently serves on the board of Aevi Genomic Medicine, Inc., Jounce Therapeutics, Inc., Adaptimmune Therapeutics plc, Innoviva, Inc. and ObsEva SA. Ms. Duncan received her B.S. from Louisiana State University and her MBA from the Wharton School of the University of Pennsylvania.

Matthew During, M.D., D.Sc., is our founder and was appointed as our chief scientific officer in March 2015 and has served as our president and a member of our board of directors since April 2014. From April 2014 to March 2015, he served as our chief executive officer. Prior to founding our company, Dr. During founded NightstaRx Limited, a pharmaceutical company, in October 2013 and served as a consultant until November 2015. From February 2014 to December 2014, Dr. During served as a senior manager at Bridgewater Associates. Prior to that, he founded Neurologix, Inc., a pharmaceutical company, in October 1999 and served as a member of its scientific advisory board until March 2012. Dr. During also co-founded Merlin Pharmaceuticals (P) Limited, a pharmaceutical company, in February 1993 and served a member of its scientific advisory board until December 1994. Dr. During previously served on the faculty of Yale University as Professor of Neurosurgery from 1989 to 2000, as a Professor at Cornell University until 2006 and Ohio State University from 2006 to December 2014, where he currently serves as an adjunct professor. Since 2011, he has also served as a visiting professor of translational neuroscience at the University of Oxford. Dr. During earned his B.S., M.D. and D.Sc. from the University of Auckland. He also completed fellowships at Massachusetts Institute of Technology and Harvard Medical School.

Bart Friedman, J.D., has served as a member of our board of directors since November 2015. Mr. Friedman was a partner at Cahill Gordon & Reindel LLP, a New York law firm, since 1980 and became senior counsel as of January 2017. Mr. Friedman’s practice focuses on corporate governance investigations and advisory and crisis advisory. Earlier in his career, Mr. Friedman worked at the Securities and Exchange Commission, initially as special counsel and later as assistant director. Mr. Friedman currently serves as chairman of the board of directors of the Sanford C. Bernstein Mutual Funds and as the lead director of the board of directors of Allied World Assurance Company Holdings, AG, a publicly held company. He currently serves as chair of the audit committee of the Brookings Institution, chair of the audit committee of Lincoln Center for the Performing Arts and treasurer of the Smithsonian’s Cooper-Hewitt Museum. Mr. Friedman earned his A.B. from Long Island University and his J.D. from Harvard Law School.

Douglas Williams, Ph.D. has served as a member of our board of directors since January 2016. Dr. Williams is currently a member on the board of directors of each of Ironwood Pharmaceuticals, Inc. and Regulus Therapeutics Inc., each a publicly held biotechnology company. Dr. Williams is president, chief executive officer and a member of the board of directors of Codiak Biosciences, Inc., a biotechnology company, which was founded in November 2015. Prior to that, he served as Biogen Inc.’s executive vice president, research and development from January 2011 to July 2015. From 2004 to 2010, Dr. Williams served in various roles at ZymoGenetics, Inc., a former publicly held pharmaceutical company, and a subsidiary of Bristol-Myers Squibb Company, a publicly held pharmaceutical company, most recently in the role of chief executive officer and a member of its board of directors. Dr. Williams also served as a member of the board of directors of each of Oncothyreon Inc. and Array BioPharma Inc. Previously, Dr. Williams held senior leadership positions within the biotechnology industry, including chief scientific officer and executive vice president of research and development at Seattle Genetics, Inc., a publicly held biotechnology company, senior vice president and Washington site leader at Amgen, Inc., a publicly held biopharmaceutical company, and executive vice president and chief technology officer at Immunex Corporation, a publicly held pharmaceutical company, which was acquired by Amgen Inc. in 2002. Dr. Williams earned his B.S. in biological sciences from the University of Massachusetts, Lowell and his Ph.D. in physiology from the State University of New York at Buffalo, Roswell Park Memorial Institute Division.

Scientific Advisory Board

Howard Federoff, M.D., Ph.D., is the chairman of the scientific advisory board for Ovid Therapeutics. He is also vice chancellor for health affairs and dean of the School of Medicine at the University of California at Irvine, where he has oversight of the clinical, medical educational and research missions. Prior to UCI, Howard was the executive vice president for health sciences at Georgetown University and executive dean of the School of Medicine, where he was a professor of neurology. Prior to Georgetown, he held appointments as senior associate dean; professor of neurology, medicine, microbiology and immunology; professor of oncology and genetics at the University of Rochester School of Medicine; founding director of the Center for Aging and Development Biology at the Aab Institute of Biomedical Sciences; and founding division chief of molecular medicine and gene therapy. His research interests include gene therapy and neurodegenerative diseases. He has published more than 250 peer-reviewed and invited articles and serves as a reviewer for many journals as well as on the editorial board of five journals. Howard served as chair of the NIH Recombinant DNA Advisory Committee from 2007-2010. He chairs the Gene Therapy Resource Program for NHLBI, was president of the American Society for Neural Therapy and Repair from 2013 to 2013 and is president of the American Society for Experimental Neurotherapeutics. Dr. Federoff received his M.S., Ph.D. and M.D. degrees from the Albert Einstein College of Medicine, did his internship, residency and clinical and research fellowships at Massachusetts General Hospital (MGH)/Harvard Medical School, and practiced medicine at MGH, Albert Einstein and Strong Memorial Hospital at the University of Rochester. He is a Fellow of the AAAS and National Academy of Inventors.

Matthew During, M.D., D.Sc., is our founder and was appointed as our chief scientific officer in March 2015 and has served as our president and a member of our board of directors since April 2014. From April 2014 to March 2015, he served as our chief executive officer. Prior to founding our company, Dr. During founded NightstaRx Limited, a pharmaceutical company, in October 2013 and served as a consultant until November 2015. From February 2014 to December 2014, Dr. During served as a senior manager at Bridgewater Associates. Prior to that, he founded Neurologix, Inc., a pharmaceutical company, in October 1999 and served as a member of its scientific advisory board until March 2012. Dr. During also co-founded Merlin Pharmaceuticals (P) Limited, a pharmaceutical company, in February 1993 and served a member of its scientific advisory board until December 1994. Dr. During previously served on the faculty of Yale University as Professor of Neurosurgery from 1989 to 2000, as a Professor at Cornell University until 2006 and Ohio State University from 2006 to December 2014, where he currently serves as an adjunct professor. Since 2011, he has also served as a visiting professor of translational neuroscience at the University of Oxford. Dr. During earned his B.S., M.D. and D.Sc. from the University of Auckland. He also completed fellowships at Massachusetts Institute of Technology and Harvard Medical School.

David Eidelberg, M.D. is internationally recognized for his pioneering work using functional brain networks as biomarkers of neurological disease. Using PET and fMRI, he and his colleagues have identified and validated specific network biomarkers for Parkinson’s disease, Huntington’s disease, dystonia and Tourette syndrome, as well as cognitive disorders such as Alzheimer’s disease and fronto-temporal dementia. His work has led to accurate network-based algorithms for early diagnosis and assessment of disease progression in individuals with these disorders.

Dr. Eidelberg received his medical degree from Harvard Medical School. After completing residency training in neurology at Harvard, he pursued postdoctoral training in brain imaging with MRI (National Hospital, London) and PET (Cornell, New York). He has led the Center for Neurosciences at The Feinstein Institute for Medical Research since its founding in 2001, serving as director and Susan and Leonard Feinstein professor of neurology and neuroscience. Since 1995, Dr. Eidelberg has received over $15 million in research support from the NIH and other prominent funding agencies. He is the author of over 350 peer-reviewed research articles, editorials and reviews, as well as a textbook (Brain Imaging in Parkinson’s Disease, Oxford University Press 2011). He serves on the editorial boards of several high-impact journals in the neurology, neuroscience and brain imaging space, and is a scientific advisor to the Michael J. Fox Foundation, the Department of Defense, and the COBRE Center for Neurodegeneration and Translational Neuroscience (CNTN).

Jacqueline A. French, M.D., is a professor in the department of neurology, director of translational research & clinical trials in epilepsy and a neurologist at the Comprehensive Epilepsy Center at the New York University (NYU) Langone Medical Center. She is also a founder and director of the Clinical Trials Consortium, an academic group that has performed a number of early-phase clinical trials in epilepsy, and she currently serves as chief scientific officer of the Epilepsy Foundation. Previously, Dr. French chaired an American Academy of Neurology (AAN)/American Epilepsy Society (AES) committee that developed two guidelines on the use of new antiepileptic drugs and has helped create guidelines for the International League Against Epilepsy. Dr. French was also president and served on the board of the AES and was the secretary of the American Society of Experimental Neurotherapeutics. She has authored more than 200 articles and chapters, is the editor of three books, and lectures internationally on clinical trials and the use of antiepileptic drugs. She was the 2005 recipient of the AES Service Award and the 2013 Epilepsy Foundation Hero award. Dr. French received a medical degree from Brown University. She completed her residency in neurology at Mount Sinai Hospital in New York and completed fellowships in epilepsy at Mount Sinai Hospital and Yale University.

Dr. Daniel Geschwind is the Gordon and Virginia MacDonald Distinguished Professor of neurology, psychiatry and human genetics at the UCLA School of Medicine. He is director of the Neurogenetics Program and the Center for Autism Research and Treatment (CART) and co-director of the Center for Neurobehavioral Genetics in the Semel Institute at UCLA. Dr. Geschwind is also the senior associate dean and associate vice chancellor of precision medicine in the UCLA Health System and David Geffen School of Medicine. His laboratory aims to develop a mechanistic understanding of neuropsychiatric diseases, namely autism and neurodegenerative diseases, and their relationship to the range of normal human higher cognitive function and behavior. The lab’s approach relies heavily on computational and bioinformatic methods in addition to wet laboratory experimentation. The ultimate goal is to use these integrative approaches to help develop effective therapeutics for neurologic and psychiatric disorders, focusing on autism and neurodegenerative disorders.

Dr. Geschwind is also a strong advocate for data and biomaterial sharing, having provided scientific oversight for the Autism Genetic Resource Exchange (AGRE). He has served on numerous scientific advisory boards, including the Faculty of 1000 Medicine; the executive committee of the American Neurological Association; the NIMH Advisory Council; and the NIH Council of Councils. He has published over 300 papers and serves on the editorial boards of Biological Psychiatry; Cell; Current Opinion in Genetics & Development; Human Molecular Genetics; Neurobiology of Disease; and Neuron and Science. He received the Derek Denny-Brown Neurological Scholar Award from the American Neurological Association in 2004; the Scientific Service Award from Autism Speaks in 2007; the Ruane Prize for Child and Adolescent Psychiatric Research from the Brain and Behavior foundation in 2012; the Taking on Tomorrow Innovation Award (Research/Scientific Breakthrough in Autism) -Boston Children’s Hospital in 2013; and is an elected member of the Institute of Medicine of the National Academies, USA.

Jerome B. Zeldis, M.D., Ph.D., is chief medical officer and president of clinical development at Sorrento Therapeutics. Prior to this role, Dr. Zeldis was chief executive officer of Celgene Global Health. Previously, he was chief medical officer and senior vice president of clinical research and medical affairs at Celgene Corporation and had been at Celgene since February 1997. He attended Brown University for an A.B., M.S., followed by Yale University for an M.Phil., M.D., Ph.D. in molecular biophysics and biochemistry (immunochemistry). Dr. Zeldis trained in internal medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He was assistant professor of medicine at the Harvard Medical School, associate professor of medicine at University of California, Davis, clinical associate professor of medicine at Cornell Medical School and professor of clinical medicine at the Robert Wood Johnson Medical School in New Brunswick, New Jersey. Prior to working at Celgene, Dr. Zeldis worked at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical development. He has been a board member of a few start-up biotechnology companies and is currently on the board of the Semorex Corporation, PTC Corporation, Soligenix, Trek Therapeutics and BionorPharma. He has published 122 peer reviewed articles and 24 reviews, book chapters and editorials.